Other therapeutic leads
In addition to exhaustive expression profiling of each potential candidate gene, Alethia scientists used RNA interference to determine their functional significance during osteoclast differentiation. Thus, a collection of prioritized targets was assembled exhibiting tremendous promise to become excellent candidates for the development of osteoclast-specific inhibitors. The top three targets are shown below:
The innovative approach that was exploited by Alethia ensured that a rich, diversified pipeline of osteoclast-specific targets was obtained. Thus, in addition to Siglec-15 mAb, additional mAb-based inhibitors against proteins such as TSP-50 (cell-surface protease, mAb target), AB-0027 and AB-0199 are also currently being developed in this indication.
